Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ARNA 4.01 -0.09 (-2.20%)
price chart
Needham Remains Neutral on Arena Pharmaceuticals, Inc. Following 1Q:15 ...
Needham's healthcare analyst Alan Carr weighed in today with an update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the company reported first-quarter financial results and held a conference call last night to provide a corporate update.
Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for ...  MarketWatch
Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected
Stock in Motion: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares opened the most recent trading session at 4.18 and at the time of writing the last Bid was at 4.13.
Arena Pharmaceuticals Inc (NASDAQ:ARNA) in Focus
[PRNewswire] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) provided a corporate update and reported financial results for the first quarter ended March 31, 2015.
Arena: Belviq Sales Flattening Out - Is It Sector Saturation? (ARNA)  Seeking Alpha
Arena Pharmaceuticals, Inc. Price Target Update  The Daily Rover
Arena: Belviq Sales Take Big Step Back - Advertising Needed
Arena (NASDAQ:ARNA) investors have yet another frustrating week in terms of Belviq sales to consider over the long holiday weekend.
Arena Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare ...
SAN DIEGO, May 26, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, ...
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Analyst Report) is expected to report first-quarter 2015 results on May 11. Arena Pharma's performance has been mostly disappointing in 2014 with the company missing earnings expectations in three of the last four ...
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog  Nasdaq
Why These Three Stocks Active Today? Kohl's Corp. (NYSE:KSS), Arena ...
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Biotech Equities Technical Study -- Gilead Sciences, Celgene, Novavax, Arena ...
Although Arena Pharmaceuticals Inc.'s stock has lost 8.41% in the last one month, it has advanced 0.24% in the previous three trading sessions and 22.48% on YTD basis.
Arena Pharmaceuticals Receives $6.30 Consensus Target Price from Analysts ...
Arena Pharmaceuticals logo Arena Pharmaceuticals (NASDAQ:ARNA) has earned an average rating of “Hold” from the seven brokerages that are presently covering the company, ARN reports. Two research analysts have rated the stock with a sell rating, ...
Arena Pharmaceuticals, Inc. Analyst Rating Update
As many as 6 brokerage firms have rated Arena Pharmaceuticals (NASDAQ:ARNA) at 2.5. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. Selling was recommended by 1 analysts.